Thirty years as a physician and professor of medicine and pharmacology at Vanderbilt University School of Medicine and several stints as chair of FDA advisory committees exposed Alastair Wood to the challenges and pitfalls of the drug development process. Today, as managing director of Symphony Capital, a private equity firm dedicated to the biotechnology industry, Wood spends his time working to improve that process through business savvy. "Although great science may help drive a great business, great science on its own is not enough," Wood says. Click here to read about Wood and Symphony associate Sam Hall analyze a biotech business model from conception to completion.
Katharine Gleason is the research manager of Drexel University College of Medicine's Executive Leadership in Academic Medicine (ELAM) Program for Women, where she is responsible for publishing studies evaluating ELAM's programs. Gleason holds a masters degree in public health from Boston University, and she ...
